About ZemairaWhat is Alpha-1?Patient SupportPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Receive Zemaira at no charge for up to 2 weeks.

Zemaira® Sample Program

We are pleased to provide the Alpha-1 community with the option of trying Zemaira® at no charge for up to 2 weeks.* Switching to Zemaira® is easy, and participation in the Zemaira® Sample Program will not jeopardize your current Alpha-1 product supply.

How to get your Zemaira® Trial Pack

  1. Sign up for the Zemaira® Sample Program. You will receive an e-mail with a Zemaira® Product Sample Request to take to your doctor and additional information about getting your Trial Pack.
  2. Ask your doctor to fill out the Product Sample Request Form and fax it to our Customer Support group.
  3. We will ship your Zemaira® Trial Pack directly to your doctor within 1 week of receiving the request.
  4. Talk with your doctor to determine how and where you will receive Zemaira® infusions.

If you have any questions or would like more information, please call 1-866-ZEMAIRA (1-866-936-2472).

Sign up now to experience Zemaira® for yourself.

Should you decide to continue therapy with Zemaira®, you will be eligible to participate in the Alpha-1 Guardian Program and the CSL Behring AssuranceSM Program.

* This offer is valid for a limited time and applies only to patients not currently on therapy with Zemaira®.
Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available.

Zemaira® may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.